We here discuss the current state of art of DR efforts in RTT, CDD and FOXG1-syndrome, with particular emphasis on the shared molecular pathways and the identification of common drug targets across the three conditions. This evidence concerns the gene FOXG1 and craniodiaphyseal dysplasia.